Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Magazines
Fall Home Improvements
Women
Home & Realty
Outdoor Guide
Premier Home Style Tour 2024
Spring Home & Garden Show
Spring on the Road
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
Parcel Pickup
2024 Readersâ Choice
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Belite Bio, Inc
Belite Bio Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
November 12, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
November 05, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
November 03, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Presentations at the American Academy of Ophthalmology 2024 Annual Meeting
October 14, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Maxim Group 2024 Healthcare Virtual Summit
October 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces First Patient Dosed in Phase 2/3 DRAGON II Trial of Tinlarebant for the Treatment of Stargardt Disease
September 10, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in Three Upcoming Investor Conferences
September 03, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
September 01, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
August 09, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Present at the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
August 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
August 05, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Present at the JonesHealthcare Seaside Summit
July 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Receives Sakigake (Pioneer Drug) Designation of Tinlarebant for Stargardt Disease in Japan
June 12, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Benchmark’s 4th Annual Healthcare House Call Investor Conference
May 14, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports First-Quarter 2024 Financial Results and Provides Corporate Update
May 13, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor Conference
May 13, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on May 14, 2024, to Discuss First Quarter 2024 Financial Results
May 08, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in Key Opinion Leader Webinar to Discuss Unmet Needs In Stargardt Disease (STGD1) and Geographic Atrophy (GA) and Perspectives On Tinlarebant
May 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Presents Additional Analysis from Phase 2 Study of Tinlarebant in Stargardt Disease at the ARVO Annual Meeting
May 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Presentation at the Association for Research in Vision and Ophthalmology 2024 Annual Meeting
May 01, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces $25 Million Registered Direct Offering
April 25, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces PMDA Submission of Tinlarebant for Stargardt Disease Clinical Trial in Japan
March 22, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
March 11, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
March 11, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Host Webcast on March 12, 2024, to Discuss Fourth Quarter and Full Year 2024 Financial Results
March 06, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Leerink Partners Global Biopharma Conference
March 04, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
February 07, 2024
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference
November 30, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio to Participate in the BTIG Ophthalmology Day
November 20, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results
November 13, 2023
From
Belite Bio, Inc
Via
GlobeNewswire
Tickers
BLTE
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.